Renascience Inc.
4889 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 仙台市青葉区星陵町２−１
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Renascience Inc. is a Japanese company focused on innovative solutions and advancements in various sectors. With a strong emphasis on research and development, Renascience is dedicated to advancing its projects through a robust pipeline, ensuring cutting-edge results. The company prides itself on its unique business model, which underscores its strengths and capabilities in the market. Committed to transparency, Renascience provides insights into its corporate activities and introduces its management team, showcasing the expertise behind its strategic direction. By fostering a culture of innovation and collaboration, Renascience Inc. aims to lead the way in technological and scientific progress, contributing positively to society and the economy.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-27 08:35 |
Inside Information Statement
臨時報告書
|
Japanese | 23.6 KB | |
| 2025-06-24 08:36 |
Internal Control over Financial Reporting
内部統制報告書－第26期(2024/04/01－2025/03/31)
|
Japanese | 23.2 KB | |
| 2025-06-24 08:35 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2025-06-24 08:33 |
Annual Report
有価証券報告書－第26期(2024/04/01－2025/03/31)
|
Japanese | 3.5 MB | |
| 2024-11-14 07:37 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-11-14 07:36 |
Interim Report
半期報告書－第26期(2024/04/01－2025/03/31)
|
Japanese | 288.9 KB | |
| 2024-06-28 04:56 |
Inside Information Statement
臨時報告書
|
Japanese | 24.5 KB | |
| 2024-06-28 04:32 |
Internal Control over Financial Reporting
内部統制報告書－第25期(2023/04/01－2024/03/31)
|
Japanese | 22.7 KB | |
| 2024-06-28 04:26 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-06-28 04:24 |
Annual Report
有価証券報告書－第25期(2023/04/01－2024/03/31)
|
Japanese | 3.5 MB | |
| 2024-05-27 10:10 |
Inside Information Statement
臨時報告書
|
Japanese | 22.4 KB | |
| 2024-02-08 07:46 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-02-08 07:45 |
Quarterly Report
四半期報告書－第25期第3四半期(2023/10/01－2023/12/31)
|
Japanese | 235.8 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP | |
| ASKA Pharmaceutical Holdings CO., Ltd. | Japan | 4886 | ||
|
Astellas Pharma Inc. | Japan | 4503 | |
|
AstraZeneca PLC | United Kingdom | AZN | |
|
Basilea Pharmaceutica AG | Switzerland | BSLN | |
|
Bayer AG | Germany | BAY | |
|
Biofarm S.A. | Romania | BIO | |
|
Biogened Spolka Akcyjna | Poland | BGD |